Felix Seelemeyer
Papers
3
Total Citations
72
H-Index
3
About
Felix Seelemeyer is a leading urologic oncologist whose research focuses on refining treatment strategies for testicular cancer, particularly seminoma. His major contributions center on establishing primary retroperitoneal lymph node dissection (RPLND) as a viable, less-toxic alternative to chemotherapy or radiation for patients with clinical stage IIA/B metastatic seminoma. As the principal investigator of the landmark COTRIMS (Cologne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma) trial, Seelemeyer has generated pivotal prospective data demonstrating the oncologic safety and efficacy of RPLND in this setting. His 2023 publication detailing COTRIMS results has already garnered 57 citations, reflecting its immediate impact on clinical practice. Additionally, his collaborative work combining SWENOTECA and Cologne data has helped define the role of primary RPLND for tumors up to 3cm, further challenging traditional treatment paradigms. By providing high-level evidence for surgery as a frontline option, Seelemeyer is directly reducing long-term toxicities from systemic therapy while maintaining excellent cure rates. His work positions him at the forefront of testicular cancer management, offering patients a nerve-sparing, morbidity-sparing path to cure.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3